Efficacy and effects of Ritlecitinib

Ritlecitinib (Ritlecitinib) is indicated for the treatment of severe alopecia areata (AA) in adults and adolescents aged 12 years and above. Prescription information should be prescribed by a physician experienced in the diagnosis and treatment of alopecia areata. The trade name is Litfulo and will be provided in the form of 50 mg hard capsules. The active substance of ritlecitinib is ritlecitinib, which is a Janus-associated kinase (JAK) inhibitor.

Alopecia areata is a disease that causes hair loss on the scalp or other parts of the body. Ritexitinib irreversibly and selectively inhibitsJAK 3 and tyrosine kinase expression in hepatocellular carcinoma (TEC) families by blocking gamma-common cytokine signaling and reducing the cytolytic activity of NK and CD8+ cells. Although the complete pathophysiology of alopecia areata remains unclear, both JAK3 and TEC family-mediated signaling pathways are thought to be involved. The benefit of ritixitinib compared to placebo was its ability to regenerate lost hair, as shown in a Phase 2b/3 randomized, double-blind, dose-ranging study in patients with alopecia areata. The most common side effects were diarrhea, acne, upper respiratory tract infection, hives, rash, folliculitis, and dizziness.

Ritexitinib is metabolized by cytochrome P450 (CYP) and glutathione S-transferase (GST), and no single pathway contributes more than 25% to the total metabolism of ritexitinib. Since ritexitinib is a new drug for the treatment of alopecia areata, it has not yet been marketed in China and has not been included in medical insurance. Its price has not yet been learned. For specific prices and drug details, you can consult a medical consultant.